ABVC BioPharma (ABVC) vs CervoMed (CRVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ABVC BioPharma (ABVC) has outperformed CervoMed (CRVO) over the past year, losing 67.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -97.3% for ABVC. ABVC BioPharma is the larger company by market cap ($23.4 million vs $22.1 million), about 1.1 times the size.
CervoMed converts more of its revenue into profit, with a net margin of -673.1% versus -2671.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | CRVO |
|---|---|---|
| Share price | $0.8663 | $1.46 |
| Market cap | $23.37M | $22.09M |
| 1-day change | -1.56% | +9.77% |
| YTD return | -59.33% | -81.52% |
| 1-year return | -67.80% | -83.56% |
| 5-year return | -97.29% | -95.01% |
| EPS (TTM) | $-0.20 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | $4.01M |
| Revenue growth (YoY) | -41.91% | -58.86% |
| Net income (latest FY) | $-7.91M | $-26.97M |
| Operating margin | -2415.97% | -706.22% |
| Net margin | -2671.81% | -673.06% |
| 52-week high | $2.87 | $10.00 |
| 52-week low | $0.707 | $1.27 |
| Distance from 52-week high | -69.82% | -85.40% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +954.79% |
| Average volume | 81.92K | 489.10K |
| Shares outstanding | 26.98M | 15.13M |
| Employees | 16 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABVC has outperformed CRVO by 15.8 percentage points over the past year.
- CervoMed is more profitable, keeping -673.1 cents of every revenue dollar as net income versus -2671.8 cents for ABVC BioPharma.
- ABVC BioPharma grew revenue faster in its latest fiscal year (-41.91% vs -58.86%).
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ABVC vs CRVO FAQ
Which is bigger, ABVC BioPharma or CervoMed?
ABVC BioPharma (ABVC) is larger, with a market capitalization of $23.37M compared with $22.09M for CervoMed (CRVO).
Which stock has performed better over the past year, ABVC or CRVO?
ABVC returned -67.80% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and CervoMed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.